-
Study aim
-
Improving the quality of life of patients
-
Design
-
Triple blinded intervention
Randomize clinical Trial -triple blinded - controlled
Simple randomization of available patients
Phase 3
-
Settings and conduct
-
From the hospitals and offices of oncologists in Qom, the files of all cancer patients who have sought treatment for chemotherapy drugs, including Capecitabine Dejar Syndrome, have been extracted, and eligible patients are divided into intervention and control groups. Demographic information, type and stage of cancer of patients will be recorded.
-
Participants/Inclusion and exclusion criteria
-
معیارهای ورود:
تمام بیماران بالای 18 سال مبتلا به سندروم دست و پای ناشی از شیمی درمانی، از جمله داروی Capecitabine، که رضایت به شرکت در مطالعه دارند.
معیارهای عدم ورود:
بیماران مبتلا به دیگر ضایعات پوستی- وجود عفونت- بیماری التهابی روده- سابقه حساسیت شدیدبه شیر
Inclusion criteria:
All patients over 18 years of age with chemotherapy-induced hand and foot syndrome, including Capecitabine, who agree to participate in the study.
Criteria for not entering:
Patients with other skin lesions - Infection - Inflammatory bowel disease - History of severe milk allergy
-
Intervention groups
-
The intervention group consumes 15 grams of malt powder twice a day, in the morning and in the evening, which should be dissolved in 100 cc of lukewarm boiled water, and sip, and eat something until one hour after consumption. Do not use. Mercury will be used for 6 weeks and 2 days. At the same time, both control and intervention groups, 20% glycerin ointment; Use topically.
-
Main outcome variables
-
Common Terminology Criteria for Adverse Event, Edition 5, including the definition of three degrees of the syndrome, grades 1, 2, and 3, to assess the degree of lesion
Pain rate,
Evaluation of redness and scaling of skin lesions
Evaluation of burning, itching and, numbness of skin lesions